Aspira Women's Health: Director Departs, New Director Appointed

Ticker: AWHL · Form: 8-K · Filed: 2025-09-03T00:00:00.000Z

Sentiment: neutral

Topics: board-change, management

TL;DR

Aspira Women's Health board shake-up: Gelfond out, Smith in.

AI Summary

Aspira Women's Health Inc. announced on September 2, 2025, the departure of Director Dr. Jonathan M. Gelfond and the appointment of Dr. David L. Smith as a new director. The company also reported on compensatory arrangements for certain officers.

Why It Matters

Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: low — This filing primarily concerns routine board and officer changes, with no immediate financial distress or significant operational shifts indicated.

Key Players & Entities

FAQ

Who is Dr. David L. Smith and what is his background?

The filing does not provide specific details about Dr. David L. Smith's background or qualifications beyond his appointment as a director.

What were the reasons for Dr. Jonathan M. Gelfond's departure?

The filing states Dr. Jonathan M. Gelfond's departure but does not specify the reasons for his exit.

Are there any new compensatory arrangements for officers detailed in this filing?

The filing mentions 'Compensatory Arrangements of Certain Officers' as an item, but the specific details of these arrangements are not provided in the excerpt.

What is the significance of the 'Election of Directors' item?

This item indicates that the company has elected new directors to its board, which is a governance-related event.

When was the earliest event reported in this Form 8-K?

The earliest event reported in this Form 8-K occurred on September 2, 2025.

From the Filing

0001641172-25-026441.txt : 20250903 0001641172-25-026441.hdr.sgml : 20250903 20250903172230 ACCESSION NUMBER: 0001641172-25-026441 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250902 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250903 DATE AS OF CHANGE: 20250903 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aspira Women's Health Inc. CENTRAL INDEX KEY: 0000926617 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences EIN: 330595156 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34810 FILM NUMBER: 251291076 BUSINESS ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 512-519-0400 MAIL ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: VERMILLION, INC. DATE OF NAME CHANGE: 20070824 FORMER COMPANY: FORMER CONFORMED NAME: CIPHERGEN BIOSYSTEMS INC DATE OF NAME CHANGE: 20000316 FORMER COMPANY: FORMER CONFORMED NAME: ABIOTIC SYSTEMS DATE OF NAME CHANGE: 19950407 8-K 1 form8-k.htm 8-K false 0000926617 0000926617 2025-09-02 2025-09-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       Form 8-K       CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): September 2, 2025       Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter)       Delaware   001-34810   33-0595156 (State or other jurisdiction   (Commission   (IRS Employer of incorporation)   File Number)   Identification No.)   12117 Bee Caves Road , Building III , Suite 100 , Austin , Texas   78738 (Address of principal executive offices)   (Zip Code)   Registrant’s telephone number, including area code: (512) 519-0400       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   AWHL   The OTC QB Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangemen

View on Read The Filing